cmAngio® vs DeepTek CXR Analyzer
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary objective is to leverage existing mammography screenings to assess a woman's cardiovascular health by detecting Breast Arterial Calcifications (BAC). This tool is ideal for integrating cardiovascular risk assessment into routine breast imaging workflows without requiring additional radiation or procedures, aiding in early risk stratification.
View cmAngio® →Choose DeepTek CXR Analyzer if…
Choose DeepTek CXR Analyzer if your goal is to significantly enhance the efficiency and accuracy of chest X-ray interpretation across a broad spectrum of lung, pleural, and cardiac pathologies. This solution is best suited for radiology departments aiming to reduce radiologist workload and boost productivity by automatically identifying and highlighting suspicious regions on various X-ray modalities.
View DeepTek CXR Analyzer →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | DeepTek CXR Analyzer |
|---|---|---|
| Pricing | Paid, out-of-pocket | Global access pricing available for eligible public sector and not-for-profit healthcare providers in 138 low- and middle-income countries, offering unlimited ai analyses per connected x-ray unit, installation, user training, product updates, maintenance, and technical support via an annual subscription. |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | On-premise and Cloud offerings. The solution supports online, offline, and hybrid deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieBoth tools emphasize ease of integration and interpretation. Tool A highlights quick installation and adjustable operating points for clinical goals, while Tool B focuses on seamless PACS integration and intelligent segregation of scans for easier interpretation. Without direct user feedback or detailed comparative studies, both appear to offer strong usability features.
Clinical Value
DeepTek CXR AnalyzerDeepTek CXR Analyzer offers a broader range of 28 findings across lung, pleural, and cardiac pathologies on chest X-rays, with clear metrics for reducing radiologist workload by 30-50% and boosting productivity by 2x-3%. While cmAngio provides a novel application for cardiovascular risk assessment from mammograms, DeepTek's wider applicability to common pathologies and quantifiable efficiency gains give it a stronger overall clinical value.
Pricing & Value
DeepTek CXR AnalyzerDeepTek CXR Analyzer explicitly offers a 'pay-per-use' model, which typically provides greater transparency and flexibility for varying workloads. cmAngio's pricing is not publicly available, though it mentions limited-time offers for no-cost implementation and service. The clear pay-per-use structure of Tool B suggests better value transparency and adaptability for budgeting and scaling.
Enterprise Readiness
DeepTek CXR AnalyzerDeepTek CXR Analyzer offers both cloud and on-premise deployment options, providing greater flexibility for diverse enterprise IT environments and security requirements. Both tools are FDA-cleared, HIPAA-compliant, and integrate with DICOM, but Tool B's dual deployment model is a significant advantage for enterprise adoption and catering to varied infrastructure preferences.
Innovation
cmAngio®cmAngio presents a more innovative application by leveraging existing mammograms to detect Breast Arterial Calcifications for cardiovascular risk assessment, unlocking new clinical insights from routine exams. While DeepTek CXR Analyzer offers comprehensive chest X-ray analysis, the core concept of CADe for chest X-rays is a more established AI application. Tool A's novel use case for cardiovascular health assessment stands out as more innovative.
Support & Docs
DeepTek CXR AnalyzerDeepTek's resources include a 'Gateway Download & Installation Guide' and mentions of a 'user manual' in FDA documents, along with a 'Resources Hub' on their website that lists a 'Knowledge Base'. CureMetrix mentions an 'Operator's Manual' but less publicly available information on a comprehensive support or documentation portal. DeepTek appears to offer more explicit and accessible documentation and resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | DeepTek CXR Analyzer |
|---|---|---|
| Product Name | cmAngiou00ae | DeepTek CXR Analyzer |
| Company | CureMetrix | DeepTek Medical Imaging Pvt |
| Primary AI Focus | Detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | AI-powered CADe solution for chest X-ray analysis, designed to assist radiologists by automatically detecting and highlighting suspicious regions across lung, pleural, and cardiac pathologies. |
| Target Modality | Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | Chest X-rays (compatible with various X-ray modalities: hospital, mobile, portable, handheld) |
| Key Detections/Findings | AI-based detection of Breast Arterial Calcifications (BAC); Provides visualization of BAC location on a scorecard. | Detection of 28 findings covering lung, pleural, cardiac pathologies, and hardware; Automatic identification, categorization, and highlighting of suspicious regions of interest (ROIs). |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and DeepTek CXR Analyzer.